8/13/2025, 5:00:45 AM | www.tradingview.com | news

Evotec SE reports H1 2025 results: Strong progress on strategy execution

Evotec SE has announced its first-half 2025 financial results, showing progress in executing its strategy for sustainable and profitable growth. The company reports a 5.0% decrease in group revenues to €371.2 million, driven by soft demand in its D&P&D segment, which declined 11.0% to €269.0 million. Just – Evotec Biologics, a key growth driver, saw a 16% revenue increase to €102.2 million, with strong performance from non-Sandoz and non-DoD customers. Adjusted Group EBITDA was €(1.9) million, in line with expectations due to strong cost control. Evotec also announced a potential sale of Just – Evotec Biologics' EU operations, including its Toulouse biologics manufacturing site, for around US$300 million in cash plus future technology-related payments. The company reported significant progress in collaborations with Bristol Myers Squibb (BMS), including a US$75 million performance-based and program-based payment and a US$20 million research payment. Evotec received a grant from The Gates Foundation to support tuberculosis treatment development and joined the NURTuRE-AKI consortium to expand its Molecular Patient Database. The company welcomed the FDA's roadmap to reduce animal testing, aligning with its long-term commitment to New Approach Methodologies (NAMs) and the 3-Rs principles. Evotec expects full-year group revenues between €760 million and €800 million, R&D spending between €40 million and €50 million, and adjusted EBITDA between €30 million and €50 million.